NCT07145385Not yet recruiting
Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer
Prevalence of Alpha-1 Antitrypsin Deficiency in a Cohort of Hepatocellular Carcinoma on Non-Cirrhotic Liver Without Identified Etiologies
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 71 (estimated)
- First submitted
- 27 Jun 2025
- Start date
- Jan 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07145385
What you commit to
- Study type: Observational
- Planned participants: 71
- From Jan 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No signed informed consent prior to participation.
Other illness
- Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue.
- Presence of other identified etiologies or known risk factors for liver disease, including:
- Alcohol-related liver disease
- Metabolic-associated steatohepatitis (MASH)
- Viral hepatitis infections
- Hemochromatosi
Age
- Minor patients (\<18 years of age).
Other
- HCC diagnosis not established according to standard histopathological criteria.
Who the study is looking for
- Adult patients (≥18 years of age).
- Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC).
- Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue.
- Signed informed consent obtained prior to participation.
- No other known etiology or risk factors for liver disease, including:
- Alcohol-related liver disease
- Metabolic-associated steatohepatitis (MASH)
- Viral hepatitis infections
- Hemochromatosis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Bordeaux Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
Related publications
- Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort.J Clin Exp Hepatol · 2026 · PMID 42064227
This page is information, not medical advice. Discuss any trial with your doctor.